Recursion Pharmaceuticals (RXRX) Cash from Investing Activities (2020 - 2026)

Recursion Pharmaceuticals' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$338000.0 for Q1 2026.

• Quarterly Cash from Investing Activities rose 95.35% year-over-year to -$338000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.9 million (down 103.83% YoY) and the FY2025 annual result came in at -$16.9 million, down 106.49% from the prior year.
• Cash from Investing Activities was -$338000.0 for Q1 2026 at Recursion Pharmaceuticals, up from -$1.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $275.5 million in Q4 2024 and bottomed at -$8.0 million in Q4 2022.
• A 5-year average of $25.1 million and a median of -$2.5 million in 2023 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 11171.38% in 2024, while the deepest fall reached 1214.7% in 2024.
• Recursion Pharmaceuticals' Cash from Investing Activities stood at -$8.0 million in 2022, then jumped by 68.82% to -$2.5 million in 2023, then surged by 11171.38% to $275.5 million in 2024, then tumbled by 100.45% to -$1.2 million in 2025, then surged by 72.83% to -$338000.0 in 2026.
• Business Quant data shows RXRX's Cash from Investing Activities at -$338000.0 in Q1 2026, -$1.2 million in Q4 2025, and -$2.5 million in Q3 2025.